R&D Pipeline Overview

Through in-licensing from either big pharma/biotech companies or academic institutions, we have established a robust and science-driven portfolio that targets the underlying causes of the various orphan diseases with few or no approved therapeutic options. We are also leveraging sponsored collaboration and research with universities to help de-risk potential projects before their adoption into our pipeline.

Development Programs

Animal POC

IND Enabling

Phase 1

Phase 2

Phase 3

Small molecules

Biologics

Exploratory Programs

LM-070 ERT

LM-014 ERT

Lead Selection

Animal POC

Pre-Clinical

Phase I

Phase II

Phase III

Lead Selection

Animal POC

Pre-Clinical

Phase I

Phase II

Phase III

ARPKD

Lead Selection

Animal POC

Pre-Clinical

Phase I

Phase II

Phase III

Lead Selection

Animal POC

Pre-Clinical

Phase I

Phase II

Phase III

Lead Selection

Animal POC

Pre-Clinical

Phase I

Phase II

Phase III

ODD

RPD

ODD: Orphan Drug Designation; RPD: Rare Pediatric Designation; FTD: Fast Track Designation

Exploratory Programs

LM-070 ERT

LM-014 ERT

Treating Orphan Diseases With Few or No Options.

map.png

Redwood City, CA, USA

map.png

Taipei, Taiwan

©2020 BY LIFEMAX HEALTHCARE INTERNATIONAL